#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Atherosclerosis is a common pathology that affects large and medium arteries leading to a variety of cardiovascular events that can also be fatal , therefore representing a serious public health problem .
3-1	17-32	Atherosclerosis	abstract	new	coref	3-3[4_0]
3-2	33-35	is	_	_	_	_
3-3	36-37	a	abstract[4]	giv[4]	coref	4-1[0_4]
3-4	38-44	common	abstract[4]	giv[4]	_	_
3-5	45-54	pathology	abstract[4]	giv[4]	_	_
3-6	55-59	that	_	_	_	_
3-7	60-67	affects	_	_	_	_
3-8	68-73	large	object[5]	new[5]	_	_
3-9	74-77	and	object[5]	new[5]	_	_
3-10	78-84	medium	object[5]	new[5]	_	_
3-11	85-93	arteries	object[5]	new[5]	_	_
3-12	94-101	leading	_	_	_	_
3-13	102-104	to	_	_	_	_
3-14	105-106	a	event[6]	new[6]	_	_
3-15	107-114	variety	event[6]	new[6]	_	_
3-16	115-117	of	event[6]	new[6]	_	_
3-17	118-132	cardiovascular	event[6]|event[7]	new[6]|new[7]	coref	6-16[30_7]
3-18	133-139	events	event[6]|event[7]	new[6]|new[7]	_	_
3-19	140-144	that	_	_	_	_
3-20	145-148	can	_	_	_	_
3-21	149-153	also	_	_	_	_
3-22	154-156	be	_	_	_	_
3-23	157-162	fatal	_	_	_	_
3-24	163-164	,	_	_	_	_
3-25	165-174	therefore	_	_	_	_
3-26	175-187	representing	_	_	_	_
3-27	188-189	a	abstract[9]	new[9]	_	_
3-28	190-197	serious	abstract[9]	new[9]	_	_
3-29	198-204	public	abstract[9]	new[9]	_	_
3-30	205-211	health	abstract|abstract[9]	new|new[9]	_	_
3-31	212-219	problem	abstract[9]	new[9]	_	_
3-32	220-221	.	_	_	_	_

#Text=Atherosclerosis is characterized by progressive lipid deposition in the arterial wall , plaque induction and possible further progression to the state of so-called unstable plaque .
4-1	222-237	Atherosclerosis	abstract	giv	coref	8-13
4-2	238-240	is	_	_	_	_
4-3	241-254	characterized	_	_	_	_
4-4	255-257	by	_	_	_	_
4-5	258-269	progressive	event[12]	new[12]	_	_
4-6	270-275	lipid	person|event[12]	new|new[12]	coref	15-10
4-7	276-286	deposition	event[12]	new[12]	_	_
4-8	287-289	in	event[12]	new[12]	_	_
4-9	290-293	the	event[12]|object[13]	new[12]|new[13]	_	_
4-10	294-302	arterial	event[12]|object[13]	new[12]|new[13]	_	_
4-11	303-307	wall	event[12]|object[13]	new[12]|new[13]	_	_
4-12	308-309	,	event[12]	new[12]	_	_
4-13	310-316	plaque	event[12]|object|event[15]	new[12]|new|new[15]	coref|coref	4-23[18_0]|4-23[18_0]
4-14	317-326	induction	event[12]|event[15]	new[12]|new[15]	_	_
4-15	327-330	and	event[12]	new[12]	_	_
4-16	331-339	possible	event[12]|event[16]	new[12]|new[16]	coref	18-14[0_16]
4-17	340-347	further	event[12]|event[16]	new[12]|new[16]	_	_
4-18	348-359	progression	event[12]|event[16]	new[12]|new[16]	_	_
4-19	360-362	to	event[12]|event[16]	new[12]|new[16]	_	_
4-20	363-366	the	event[12]|event[16]|abstract[17]	new[12]|new[16]|new[17]	_	_
4-21	367-372	state	event[12]|event[16]|abstract[17]	new[12]|new[16]|new[17]	_	_
4-22	373-375	of	event[12]|event[16]|abstract[17]	new[12]|new[16]|new[17]	_	_
4-23	376-385	so-called	event[12]|event[16]|abstract[17]|object[18]	new[12]|new[16]|new[17]|giv[18]	coref	5-10[21_18]
4-24	386-394	unstable	event[12]|event[16]|abstract[17]|object[18]	new[12]|new[16]|new[17]|giv[18]	_	_
4-25	395-401	plaque	event[12]|event[16]|abstract[17]|object[18]	new[12]|new[16]|new[17]|giv[18]	_	_
4-26	402-403	.	_	_	_	_

#Text=Advanced plaques usually acquire a fibrous cap that separates the plaque from the surrounding milieu and plays a stabilizing role .
5-1	404-412	Advanced	object[19]	new[19]	coref	6-3[0_19]
5-2	413-420	plaques	object[19]	new[19]	_	_
5-3	421-428	usually	_	_	_	_
5-4	429-436	acquire	_	_	_	_
5-5	437-438	a	object[20]	new[20]	_	_
5-6	439-446	fibrous	object[20]	new[20]	_	_
5-7	447-450	cap	object[20]	new[20]	_	_
5-8	451-455	that	_	_	_	_
5-9	456-465	separates	_	_	_	_
5-10	466-469	the	object[21]	giv[21]	coref	7-19[0_21]
5-11	470-476	plaque	object[21]	giv[21]	_	_
5-12	477-481	from	_	_	_	_
5-13	482-485	the	abstract[22]	new[22]	_	_
5-14	486-497	surrounding	abstract[22]	new[22]	_	_
5-15	498-504	milieu	abstract[22]	new[22]	_	_
5-16	505-508	and	_	_	_	_
5-17	509-514	plays	_	_	_	_
5-18	515-516	a	abstract[23]	new[23]	coref	10-7[54_23]
5-19	517-528	stabilizing	abstract[23]	new[23]	_	_
5-20	529-533	role	abstract[23]	new[23]	_	_
5-21	534-535	.	_	_	_	_

#Text=Destabilization of plaques leads to their rupture with subsequent thrombus formation that can lead to dangerous events such as acute coronary syndrome ( ACS ) and stroke .
6-1	536-551	Destabilization	abstract[24]	new[24]	_	_
6-2	552-554	of	abstract[24]	new[24]	_	_
6-3	555-562	plaques	abstract[24]|object	new[24]|giv	ana	6-6
6-4	563-568	leads	_	_	_	_
6-5	569-571	to	_	_	_	_
6-6	572-577	their	object|event[27]	giv|new[27]	coref|coref	7-1[35_0]|7-1[35_0]
6-7	578-585	rupture	event[27]	new[27]	_	_
6-8	586-590	with	event[27]	new[27]	_	_
6-9	591-601	subsequent	event[27]|event[29]	new[27]|new[29]	coref	7-8[36_29]
6-10	602-610	thrombus	event[27]|abstract|event[29]	new[27]|new|new[29]	_	_
6-11	611-620	formation	event[27]|event[29]	new[27]|new[29]	_	_
6-12	621-625	that	_	_	_	_
6-13	626-629	can	_	_	_	_
6-14	630-634	lead	_	_	_	_
6-15	635-637	to	_	_	_	_
6-16	638-647	dangerous	event[30]	giv[30]	_	_
6-17	648-654	events	event[30]	giv[30]	_	_
6-18	655-659	such	event[30]	giv[30]	_	_
6-19	660-662	as	event[30]	giv[30]	_	_
6-20	663-668	acute	event[30]|abstract[32]	giv[30]|new[32]	appos	6-24[0_32]
6-21	669-677	coronary	event[30]|person|abstract[32]	giv[30]|new|new[32]	_	_
6-22	678-686	syndrome	event[30]|abstract[32]	giv[30]|new[32]	_	_
6-23	687-688	(	_	_	_	_
6-24	689-692	ACS	abstract	giv	_	_
6-25	693-694	)	_	_	_	_
6-26	695-698	and	_	_	_	_
6-27	699-705	stroke	event	new	_	_
6-28	706-707	.	_	_	_	_

#Text=Advanced complicated plaques are also characterized by the formation of the necrotic core , pathological vascular remodeling , plaque neovascularization and calcification .
7-1	708-716	Advanced	object[35]	giv[35]	coref	8-25[47_35]
7-2	717-728	complicated	object[35]	giv[35]	_	_
7-3	729-736	plaques	object[35]	giv[35]	_	_
7-4	737-740	are	_	_	_	_
7-5	741-745	also	_	_	_	_
7-6	746-759	characterized	_	_	_	_
7-7	760-762	by	_	_	_	_
7-8	763-766	the	event[36]	giv[36]	_	_
7-9	767-776	formation	event[36]	giv[36]	_	_
7-10	777-779	of	event[36]	giv[36]	_	_
7-11	780-783	the	event[36]|abstract[37]	giv[36]|new[37]	_	_
7-12	784-792	necrotic	event[36]|abstract[37]	giv[36]|new[37]	_	_
7-13	793-797	core	event[36]|abstract[37]	giv[36]|new[37]	_	_
7-14	798-799	,	event[36]	giv[36]	_	_
7-15	800-812	pathological	event[36]|abstract[38]	giv[36]|new[38]	_	_
7-16	813-821	vascular	event[36]|abstract[38]	giv[36]|new[38]	_	_
7-17	822-832	remodeling	event[36]|abstract[38]	giv[36]|new[38]	_	_
7-18	833-834	,	event[36]	giv[36]	_	_
7-19	835-841	plaque	event[36]|object|abstract[40]	giv[36]|giv|new[40]	coref|coref	16-14[115_0]|16-14[115_0]
7-20	842-860	neovascularization	event[36]|abstract[40]	giv[36]|new[40]	_	_
7-21	861-864	and	event[36]	giv[36]	_	_
7-22	865-878	calcification	event[36]|abstract	giv[36]|new	_	_
7-23	879-880	.	_	_	_	_

#Text=Elevated low-density lipoprotein ( LDL ) is known to be associated with atherosclerosis and is identified as the major source of lipids accumulating in atherosclerotic plaques .
8-1	881-889	Elevated	substance[42]	new[42]	_	_
8-2	890-901	low-density	substance[42]	new[42]	_	_
8-3	902-913	lipoprotein	substance[42]	new[42]	_	_
8-4	914-915	(	_	_	_	_
8-5	916-919	LDL	abstract	new	coref	9-2[48_0]
8-6	920-921	)	_	_	_	_
8-7	922-924	is	_	_	_	_
8-8	925-930	known	_	_	_	_
8-9	931-933	to	_	_	_	_
8-10	934-936	be	_	_	_	_
8-11	937-947	associated	_	_	_	_
8-12	948-952	with	_	_	_	_
8-13	953-968	atherosclerosis	abstract	giv	coref	10-11
8-14	969-972	and	_	_	_	_
8-15	973-975	is	_	_	_	_
8-16	976-986	identified	_	_	_	_
8-17	987-989	as	_	_	_	_
8-18	990-993	the	_	_	_	_
8-19	994-999	major	_	_	_	_
8-20	1000-1006	source	_	_	_	_
8-21	1007-1009	of	_	_	_	_
8-22	1010-1016	lipids	substance	new	_	_
8-23	1017-1029	accumulating	_	_	_	_
8-24	1030-1032	in	_	_	_	_
8-25	1033-1048	atherosclerotic	substance|object[47]	new|giv[47]	_	_
8-26	1049-1056	plaques	object[47]	giv[47]	_	_
8-27	1057-1058	.	_	_	_	_

#Text=Circulating modified LDL has increased atherogenicity in comparison to native LDL .
9-1	1059-1070	Circulating	_	_	_	_
9-2	1071-1079	modified	abstract[48]	giv[48]	coref	9-10[51_48]
9-3	1080-1083	LDL	abstract[48]	giv[48]	_	_
9-4	1084-1087	has	_	_	_	_
9-5	1088-1097	increased	_	_	_	_
9-6	1098-1112	atherogenicity	abstract	new	_	_
9-7	1113-1115	in	_	_	_	_
9-8	1116-1126	comparison	abstract[50]	new[50]	_	_
9-9	1127-1129	to	abstract[50]	new[50]	_	_
9-10	1130-1136	native	abstract[50]|abstract[51]	new[50]|giv[51]	coref	10-4[0_51]
9-11	1137-1140	LDL	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
9-12	1141-1142	.	_	_	_	_

#Text=Chemical modification of LDL likely plays a prominent role in atherosclerosis development .
10-1	1143-1151	Chemical	abstract[52]	new[52]	_	_
10-2	1152-1164	modification	abstract[52]	new[52]	_	_
10-3	1165-1167	of	abstract[52]	new[52]	_	_
10-4	1168-1171	LDL	abstract[52]|substance	new[52]|giv	coref	11-3
10-5	1172-1178	likely	_	_	_	_
10-6	1179-1184	plays	_	_	_	_
10-7	1185-1186	a	abstract[54]	giv[54]	_	_
10-8	1187-1196	prominent	abstract[54]	giv[54]	_	_
10-9	1197-1201	role	abstract[54]	giv[54]	_	_
10-10	1202-1204	in	abstract[54]	giv[54]	_	_
10-11	1205-1220	atherosclerosis	abstract[54]|abstract|abstract[56]	giv[54]|giv|new[56]	coref|coref	14-22|14-22
10-12	1221-1232	development	abstract[54]|abstract[56]	giv[54]|new[56]	_	_
10-13	1233-1234	.	_	_	_	_

#Text=Besides elevated LDL , chronic inflammation is now considered as another crucial pro-atherogenic mechanism that can even precede lipid entry into the arterial intima .
11-1	1235-1242	Besides	_	_	_	_
11-2	1243-1251	elevated	_	_	_	_
11-3	1252-1255	LDL	abstract	giv	_	_
11-4	1256-1257	,	_	_	_	_
11-5	1258-1265	chronic	abstract[58]	new[58]	ana	12-1[0_58]
11-6	1266-1278	inflammation	abstract[58]	new[58]	_	_
11-7	1279-1281	is	_	_	_	_
11-8	1282-1285	now	_	_	_	_
11-9	1286-1296	considered	_	_	_	_
11-10	1297-1299	as	_	_	_	_
11-11	1300-1307	another	_	_	_	_
11-12	1308-1315	crucial	_	_	_	_
11-13	1316-1331	pro-atherogenic	_	_	_	_
11-14	1332-1341	mechanism	_	_	_	_
11-15	1342-1346	that	_	_	_	_
11-16	1347-1350	can	_	_	_	_
11-17	1351-1355	even	_	_	_	_
11-18	1356-1363	precede	_	_	_	_
11-19	1364-1369	lipid	abstract|place[60]	new|new[60]	coref|coref	15-6|15-6
11-20	1370-1375	entry	place[60]	new[60]	_	_
11-21	1376-1380	into	_	_	_	_
11-22	1381-1384	the	place[61]	new[61]	_	_
11-23	1385-1393	arterial	place[61]	new[61]	_	_
11-24	1394-1400	intima	place[61]	new[61]	_	_
11-25	1401-1402	.	_	_	_	_

#Text=It has been proposed that disturbances of hemodynamic forces that are especially likely to occur at atheroprone sites of blood vessels , such as bends or bifurcations , can cause local activation of endothelial cells ( ECs ) .
12-1	1403-1405	It	abstract	giv	coref	14-16
12-2	1406-1409	has	_	_	_	_
12-3	1410-1414	been	_	_	_	_
12-4	1415-1423	proposed	_	_	_	_
12-5	1424-1428	that	_	_	_	_
12-6	1429-1441	disturbances	abstract[63]	new[63]	_	_
12-7	1442-1444	of	abstract[63]	new[63]	_	_
12-8	1445-1456	hemodynamic	abstract[63]|abstract[64]	new[63]|new[64]	_	_
12-9	1457-1463	forces	abstract[63]|abstract[64]	new[63]|new[64]	_	_
12-10	1464-1468	that	_	_	_	_
12-11	1469-1472	are	_	_	_	_
12-12	1473-1483	especially	_	_	_	_
12-13	1484-1490	likely	_	_	_	_
12-14	1491-1493	to	_	_	_	_
12-15	1494-1499	occur	_	_	_	_
12-16	1500-1502	at	_	_	_	_
12-17	1503-1514	atheroprone	place[65]	new[65]	_	_
12-18	1515-1520	sites	place[65]	new[65]	_	_
12-19	1521-1523	of	place[65]	new[65]	_	_
12-20	1524-1529	blood	place[65]|object[66]	new[65]|new[66]	_	_
12-21	1530-1537	vessels	place[65]|object[66]	new[65]|new[66]	_	_
12-22	1538-1539	,	place[65]|object[66]	new[65]|new[66]	_	_
12-23	1540-1544	such	place[65]|object[66]	new[65]|new[66]	_	_
12-24	1545-1547	as	place[65]|object[66]	new[65]|new[66]	_	_
12-25	1548-1553	bends	place[65]|object[66]|event	new[65]|new[66]|new	_	_
12-26	1554-1556	or	place[65]|object[66]	new[65]|new[66]	_	_
12-27	1557-1569	bifurcations	place[65]|object[66]|abstract	new[65]|new[66]|new	_	_
12-28	1570-1571	,	_	_	_	_
12-29	1572-1575	can	_	_	_	_
12-30	1576-1581	cause	_	_	_	_
12-31	1582-1587	local	abstract[69]	new[69]	_	_
12-32	1588-1598	activation	abstract[69]	new[69]	_	_
12-33	1599-1601	of	abstract[69]	new[69]	_	_
12-34	1602-1613	endothelial	abstract[69]|object[70]	new[69]|new[70]	appos	12-37[0_70]
12-35	1614-1619	cells	abstract[69]|object[70]	new[69]|new[70]	_	_
12-36	1620-1621	(	_	_	_	_
12-37	1622-1625	ECs	object	giv	coref	13-3
12-38	1626-1627	)	_	_	_	_
12-39	1628-1629	.	_	_	_	_

#Text=Consequently , ECs acquire a pro-inflammatory phenotype and start expressing different pro-inflammatory molecules , such as monocyte chemotactic protein 1 ( MCP1 ) ( also known as chemokine ( C-C motif ) ligand 2 ; CCL2 ) , intercellular adhesion molecule 1 ( ICAM-1 ) and vascular cell adhesion molecule 1 ( VCAM-1 ) , all of which attract monocytes to the activated endothelium .
13-1	1630-1642	Consequently	_	_	_	_
13-2	1643-1644	,	_	_	_	_
13-3	1645-1648	ECs	object	giv	coref	15-16[104_0]
13-4	1649-1656	acquire	_	_	_	_
13-5	1657-1658	a	abstract[73]	new[73]	coref	14-7[93_73]
13-6	1659-1675	pro-inflammatory	abstract[73]	new[73]	_	_
13-7	1676-1685	phenotype	abstract[73]	new[73]	_	_
13-8	1686-1689	and	_	_	_	_
13-9	1690-1695	start	_	_	_	_
13-10	1696-1706	expressing	_	_	_	_
13-11	1707-1716	different	substance[74]	new[74]	_	_
13-12	1717-1733	pro-inflammatory	substance[74]	new[74]	_	_
13-13	1734-1743	molecules	substance[74]	new[74]	_	_
13-14	1744-1745	,	substance[74]	new[74]	_	_
13-15	1746-1750	such	substance[74]	new[74]	_	_
13-16	1751-1753	as	substance[74]	new[74]	_	_
13-17	1754-1762	monocyte	substance[74]|substance[76]	new[74]|new[76]	_	_
13-18	1763-1774	chemotactic	substance[74]|abstract|substance[76]	new[74]|new|new[76]	_	_
13-19	1775-1782	protein	substance[74]|substance[76]	new[74]|new[76]	_	_
13-20	1783-1784	1	substance[74]|substance[76]	new[74]|new[76]	_	_
13-21	1785-1786	(	substance[74]|substance[76]	new[74]|new[76]	_	_
13-22	1787-1791	MCP1	substance[74]|substance[76]|object	new[74]|new[76]|new	_	_
13-23	1792-1793	)	substance[74]|substance[76]	new[74]|new[76]	_	_
13-24	1794-1795	(	_	_	_	_
13-25	1796-1800	also	_	_	_	_
13-26	1801-1806	known	_	_	_	_
13-27	1807-1809	as	_	_	_	_
13-28	1810-1819	chemokine	_	_	_	_
13-29	1820-1821	(	_	_	_	_
13-30	1822-1825	C-C	abstract|abstract[79]	new|new[79]	_	_
13-31	1826-1831	motif	abstract[79]	new[79]	_	_
13-32	1832-1833	)	_	_	_	_
13-33	1834-1840	ligand	abstract[80]	new[80]	appos	13-36[0_80]
13-34	1841-1842	2	abstract[80]	new[80]	_	_
13-35	1843-1844	;	_	_	_	_
13-36	1845-1849	CCL2	abstract	giv	_	_
13-37	1850-1851	)	_	_	_	_
13-38	1852-1853	,	_	_	_	_
13-39	1854-1867	intercellular	_	_	_	_
13-40	1868-1876	adhesion	substance	new	coref	13-48[85_0]
13-41	1877-1885	molecule	_	_	_	_
13-42	1886-1887	1	_	_	_	_
13-43	1888-1889	(	_	_	_	_
13-44	1890-1896	ICAM-1	event	new	ana	13-56[87_0]
13-45	1897-1898	)	_	_	_	_
13-46	1899-1902	and	_	_	_	_
13-47	1903-1911	vascular	_	_	_	_
13-48	1912-1916	cell	place|substance[85]	new|giv[85]	_	_
13-49	1917-1925	adhesion	substance[85]	giv[85]	_	_
13-50	1926-1934	molecule	_	_	_	_
13-51	1935-1936	1	_	_	_	_
13-52	1937-1938	(	_	_	_	_
13-53	1939-1945	VCAM-1	object	new	_	_
13-54	1946-1947	)	_	_	_	_
13-55	1948-1949	,	_	_	_	_
13-56	1950-1953	all	event[87]	giv[87]	_	_
13-57	1954-1956	of	event[87]	giv[87]	_	_
13-58	1957-1962	which	event[87]	giv[87]	_	_
13-59	1963-1970	attract	_	_	_	_
13-60	1971-1980	monocytes	object	new	_	_
13-61	1981-1983	to	_	_	_	_
13-62	1984-1987	the	place[89]	new[89]	_	_
13-63	1988-1997	activated	place[89]	new[89]	_	_
13-64	1998-2009	endothelium	place[89]	new[89]	_	_
13-65	2010-2011	.	_	_	_	_

#Text=The imbalance of monocyte/macrophage polarization towards the preferential pro-inflammatory phenotype and a lack of normal inflammation resolution are also present in atherosclerosis .
14-1	2012-2015	The	abstract[90]	new[90]	_	_
14-2	2016-2025	imbalance	abstract[90]	new[90]	_	_
14-3	2026-2028	of	abstract[90]	new[90]	_	_
14-4	2029-2048	monocyte/macrophage	abstract[90]|place|abstract[92]	new[90]|new|new[92]	_	_
14-5	2049-2061	polarization	abstract[90]|abstract[92]	new[90]|new[92]	_	_
14-6	2062-2069	towards	abstract[90]|abstract[92]	new[90]|new[92]	_	_
14-7	2070-2073	the	abstract[90]|abstract[92]|abstract[93]	new[90]|new[92]|giv[93]	_	_
14-8	2074-2086	preferential	abstract[90]|abstract[92]|abstract[93]	new[90]|new[92]|giv[93]	_	_
14-9	2087-2103	pro-inflammatory	abstract[90]|abstract[92]|abstract[93]	new[90]|new[92]|giv[93]	_	_
14-10	2104-2113	phenotype	abstract[90]|abstract[92]|abstract[93]	new[90]|new[92]|giv[93]	_	_
14-11	2114-2117	and	_	_	_	_
14-12	2118-2119	a	abstract[94]	new[94]	_	_
14-13	2120-2124	lack	abstract[94]	new[94]	_	_
14-14	2125-2127	of	abstract[94]	new[94]	_	_
14-15	2128-2134	normal	abstract[94]|abstract[96]	new[94]|new[96]	coref	16-6[113_96]
14-16	2135-2147	inflammation	abstract[94]|abstract|abstract[96]	new[94]|giv|new[96]	_	_
14-17	2148-2158	resolution	abstract[94]|abstract[96]	new[94]|new[96]	_	_
14-18	2159-2162	are	_	_	_	_
14-19	2163-2167	also	_	_	_	_
14-20	2168-2175	present	_	_	_	_
14-21	2176-2178	in	_	_	_	_
14-22	2179-2194	atherosclerosis	abstract	giv	coref	18-11
14-23	2195-2196	.	_	_	_	_

#Text=Phagocytic macrophages actively participate in lipid accumulation by engulfing lipid droplets and give rise to foam cells . Dendritic cells ( DCs ) contribute to the local inflammatory response through antigen presentation and cytokine signaling processes .
15-1	2197-2207	Phagocytic	object[98]	new[98]	_	_
15-2	2208-2219	macrophages	object[98]	new[98]	_	_
15-3	2220-2228	actively	_	_	_	_
15-4	2229-2240	participate	_	_	_	_
15-5	2241-2243	in	_	_	_	_
15-6	2244-2249	lipid	abstract|abstract[100]	giv|new[100]	_	_
15-7	2250-2262	accumulation	abstract[100]	new[100]	_	_
15-8	2263-2265	by	_	_	_	_
15-9	2266-2275	engulfing	_	_	_	_
15-10	2276-2281	lipid	person|object[102]	giv|new[102]	_	_
15-11	2282-2290	droplets	object[102]	new[102]	_	_
15-12	2291-2294	and	_	_	_	_
15-13	2295-2299	give	_	_	_	_
15-14	2300-2304	rise	event	new	_	_
15-15	2305-2307	to	_	_	_	_
15-16	2308-2312	foam	object[104]	giv[104]	coref	15-19[105_104]
15-17	2313-2318	cells	object[104]	giv[104]	_	_
15-18	2319-2320	.	_	_	_	_
15-19	2321-2330	Dendritic	object[105]	giv[105]	coref	18-6[122_105]
15-20	2331-2336	cells	object[105]	giv[105]	_	_
15-21	2337-2338	(	_	_	_	_
15-22	2339-2342	DCs	organization	new	_	_
15-23	2343-2344	)	_	_	_	_
15-24	2345-2355	contribute	_	_	_	_
15-25	2356-2358	to	_	_	_	_
15-26	2359-2362	the	abstract[107]	new[107]	coref	17-6[117_107]
15-27	2363-2368	local	abstract[107]	new[107]	_	_
15-28	2369-2381	inflammatory	abstract[107]	new[107]	_	_
15-29	2382-2390	response	abstract[107]	new[107]	_	_
15-30	2391-2398	through	abstract[107]	new[107]	_	_
15-31	2399-2406	antigen	abstract[107]|substance|abstract[109]	new[107]|new|new[109]	_	_
15-32	2407-2419	presentation	abstract[107]|abstract[109]	new[107]|new[109]	_	_
15-33	2420-2423	and	abstract[107]	new[107]	_	_
15-34	2424-2432	cytokine	abstract[107]|abstract|abstract[111]	new[107]|new|new[111]	coref|coref	16-10[0_111]|16-10[0_111]
15-35	2433-2442	signaling	abstract[107]|abstract[111]	new[107]|new[111]	_	_
15-36	2443-2452	processes	abstract[107]|abstract[111]	new[107]|new[111]	_	_
15-37	2453-2454	.	_	_	_	_

#Text=If the inflammatory process reaches a resolution , repair processes begin , and the plaque can become stable .
16-1	2455-2457	If	_	_	_	_
16-2	2458-2461	the	abstract[112]	new[112]	_	_
16-3	2462-2474	inflammatory	abstract[112]	new[112]	_	_
16-4	2475-2482	process	abstract[112]	new[112]	_	_
16-5	2483-2490	reaches	_	_	_	_
16-6	2491-2492	a	abstract[113]	giv[113]	_	_
16-7	2493-2503	resolution	abstract[113]	giv[113]	_	_
16-8	2504-2505	,	_	_	_	_
16-9	2506-2512	repair	_	_	_	_
16-10	2513-2522	processes	abstract	giv	_	_
16-11	2523-2528	begin	_	_	_	_
16-12	2529-2530	,	_	_	_	_
16-13	2531-2534	and	_	_	_	_
16-14	2535-2538	the	object[115]	giv[115]	coref	17-15[119_115]
16-15	2539-2545	plaque	object[115]	giv[115]	_	_
16-16	2546-2549	can	_	_	_	_
16-17	2550-2556	become	_	_	_	_
16-18	2557-2563	stable	_	_	_	_
16-19	2564-2565	.	_	_	_	_

#Text=However , failure to resolve the inflammatory response can result in the formation of the most dangerous unstable plaque that can cause thrombosis .
17-1	2566-2573	However	_	_	_	_
17-2	2574-2575	,	_	_	_	_
17-3	2576-2583	failure	event	new	_	_
17-4	2584-2586	to	_	_	_	_
17-5	2587-2594	resolve	_	_	_	_
17-6	2595-2598	the	abstract[117]	giv[117]	_	_
17-7	2599-2611	inflammatory	abstract[117]	giv[117]	_	_
17-8	2612-2620	response	abstract[117]	giv[117]	_	_
17-9	2621-2624	can	_	_	_	_
17-10	2625-2631	result	_	_	_	_
17-11	2632-2634	in	_	_	_	_
17-12	2635-2638	the	event[118]	new[118]	_	_
17-13	2639-2648	formation	event[118]	new[118]	_	_
17-14	2649-2651	of	event[118]	new[118]	_	_
17-15	2652-2655	the	event[118]|object[119]	new[118]|giv[119]	_	_
17-16	2656-2660	most	event[118]|object[119]	new[118]|giv[119]	_	_
17-17	2661-2670	dangerous	event[118]|object[119]	new[118]|giv[119]	_	_
17-18	2671-2679	unstable	event[118]|object[119]	new[118]|giv[119]	_	_
17-19	2680-2686	plaque	event[118]|object[119]	new[118]|giv[119]	_	_
17-20	2687-2691	that	_	_	_	_
17-21	2692-2695	can	_	_	_	_
17-22	2696-2701	cause	_	_	_	_
17-23	2702-2712	thrombosis	event	new	_	_
17-24	2713-2714	.	_	_	_	_

#Text=Therefore , a variety of immune cells are involved in atherosclerosis initiation and progression .
18-1	2715-2724	Therefore	_	_	_	_
18-2	2725-2726	,	_	_	_	_
18-3	2727-2728	a	abstract[121]	new[121]	_	_
18-4	2729-2736	variety	abstract[121]	new[121]	_	_
18-5	2737-2739	of	abstract[121]	new[121]	_	_
18-6	2740-2746	immune	abstract[121]|object[122]	new[121]|giv[122]	coref	19-10[129_122]
18-7	2747-2752	cells	abstract[121]|object[122]	new[121]|giv[122]	_	_
18-8	2753-2756	are	_	_	_	_
18-9	2757-2765	involved	_	_	_	_
18-10	2766-2768	in	_	_	_	_
18-11	2769-2784	atherosclerosis	abstract|abstract[124]	giv|new[124]	_	_
18-12	2785-2795	initiation	abstract[124]	new[124]	_	_
18-13	2796-2799	and	_	_	_	_
18-14	2800-2811	progression	event	giv	_	_
18-15	2812-2813	.	_	_	_	_

#Text=In this review , we consider main subsets of pro- and anti-inflammatory immune cells of myeloid origin that contribute to atherogenesis .
19-1	2814-2816	In	_	_	_	_
19-2	2817-2821	this	abstract[126]	new[126]	_	_
19-3	2822-2828	review	abstract[126]	new[126]	_	_
19-4	2829-2830	,	_	_	_	_
19-5	2831-2833	we	person	acc	_	_
19-6	2834-2842	consider	_	_	_	_
19-7	2843-2847	main	abstract[128]	new[128]	_	_
19-8	2848-2855	subsets	abstract[128]	new[128]	_	_
19-9	2856-2858	of	abstract[128]	new[128]	_	_
19-10	2859-2863	pro-	abstract[128]|object[129]	new[128]|giv[129]	_	_
19-11	2864-2867	and	abstract[128]|object[129]	new[128]|giv[129]	_	_
19-12	2868-2885	anti-inflammatory	abstract[128]|object[129]	new[128]|giv[129]	_	_
19-13	2886-2892	immune	abstract[128]|object[129]	new[128]|giv[129]	_	_
19-14	2893-2898	cells	abstract[128]|object[129]	new[128]|giv[129]	_	_
19-15	2899-2901	of	abstract[128]|object[129]	new[128]|giv[129]	_	_
19-16	2902-2909	myeloid	abstract[128]|object[129]|place|abstract[131]	new[128]|giv[129]|new|new[131]	_	_
19-17	2910-2916	origin	abstract[128]|object[129]|abstract[131]	new[128]|giv[129]|new[131]	_	_
19-18	2917-2921	that	_	_	_	_
19-19	2922-2932	contribute	_	_	_	_
19-20	2933-2935	to	_	_	_	_
19-21	2936-2949	atherogenesis	abstract	new	_	_
19-22	2950-2951	.	_	_	_	_
